Quantcast
Channel: Eli Lilly
Browsing latest articles
Browse All 36 View Live

Q&A with John Carey: Peeling back the label on cholesterol drugs

John Carey, a 20-year veteran at BusinessWeek, wrote a story that set the pharmaceutical world on its ear in January 2008. Titled "Do Cholesterol Drugs Do Any Good?," the article systematically broke...

View Article


Divided Loyalties?

A look at drug company funding for patient advocacy groups.

View Article


Q&A with Dr. Daniel Carlat: Finding an independent voice in a...

Even in his infamy, Dr. Daniel Carlat, founder of The Carlat Psychiatry Report, is popular with drug companies. Carlat was invited recently by Schering-Plough to help promote a new drug.

View Article

The Mittleman Files, Part 2: Just another day on the ghostwriting assembly line

Putting together a scientific research paper should be a different process than building a Ford Taurus or making a Big Mac.For the drug companies and their ghostwriting partners, it isn’t.

View Article

The Markingson Files: Conflicts of interest in clinical trials should be...

It can be uncomfortable asking people about their finances. In journalism, though, there is an obligation not only to ask, but to ask for proof — especially with clinical trials.

View Article


Full Disclosure: Universities Should Make Ghostwriting Disappear

Shannon Brownlee offers a not-so-modest proposal for universities to stamp out pharma ghostwriting benefiting researchers.

View Article

It's Complicated: Taking Conflict of Interest Beyond Pharma Payments to...

I wrote a piece recently for Health News Review about conflicts of interest. The original post is below, followed by more great examples of writers describing unexpected conflicts in detail.

View Article

Q&A with Leigh Turner: Tracking Medical Tourism Consequences

Bioethicist Leigh Turner, recently under fire from a stem cell company he criticized for ethical problems, talks about his research on medical tourism.

View Article

Browsing latest articles
Browse All 36 View Live